Dougherty Wealth Advisers LLC - BIO-TECHNE CORP ownership

BIO-TECHNE CORP's ticker is TECH and the CUSIP is 09073M104. A total of 560 filers reported holding BIO-TECHNE CORP in Q2 2024. The put-call ratio across all filers is 0.33 and the average weighting 0.2%.

About BIO-TECHNE CORP

Bio-Techne Corp is a leading provider of innovative life science research tools and diagnostic solutions. The company is headquartered in Minneapolis, Minnesota, and has operations in over 50 countries worldwide. Bio-Techne's products and services are used by researchers and clinicians in a wide range of fields, including cancer research, stem cell research, and immunology.

Bio-Techne's success is due in large part to its commitment to innovation and customer service. The company invests heavily in research and development, and has a team of over 1,000 scientists working to develop new products and technologies. Bio-Techne also has a strong focus on customer service, with a dedicated team of technical support specialists available to assist customers with any questions or issues they may have.

In addition to its research tools and diagnostic solutions, Bio-Techne also has a growing portfolio of clinical diagnostic products. The company's Exosome Diagnostics subsidiary is a leader in the development of liquid biopsy tests for cancer diagnosis and monitoring.

Bio-Techne's leadership team is comprised of experienced executives with a track record of success in the life sciences industry. Charles Kummeth, the company's CEO, has been with Bio-Techne since 2013 and has overseen significant growth and expansion during his tenure.

Overall, Bio-Techne is a company with a strong reputation for innovation, customer service, and leadership in the life sciences industry. With a growing portfolio of products and services, the company is well-positioned for continued success in the years to come.

It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.

Quarter-by-quarter ownership
Dougherty Wealth Advisers LLC ownership history of BIO-TECHNE CORP
ValueSharesWeighting
Q2 2024$74,229
+1.8%
1,0360.0%0.06%0.0%
Q1 2024$72,924
-8.8%
1,0360.0%0.06%
-11.0%
Q4 2023$79,938
+13.4%
1,0360.0%0.07%
-11.0%
Q3 2023$70,521
-16.6%
1,0360.0%0.08%
-29.3%
Q2 2023$84,569
+10.0%
1,0360.0%0.12%0.0%
Q1 2023$76,861
-10.5%
1,0360.0%0.12%
-17.7%
Q4 2022$85,864
+16.0%
1,036
+300.0%
0.14%
-3.4%
Q3 2022$74,000
-17.8%
2590.0%0.15%
-13.1%
Q2 2022$90,000
-19.6%
2590.0%0.17%
-0.6%
Q1 2022$112,000
-16.4%
2590.0%0.17%
-9.6%
Q4 2021$134,000
+6.3%
2590.0%0.19%0.0%
Q3 2021$126,000
+7.7%
2590.0%0.19%
+8.1%
Q2 2021$117,000
+18.2%
2590.0%0.17%
+16.1%
Q1 2021$99,000
+20.7%
2590.0%0.15%
+15.5%
Q4 2020$82,000
+28.1%
2590.0%0.13%
-41.6%
Q3 2020$64,000
-5.9%
2590.0%0.22%
-11.2%
Q2 2020$68,000
+38.8%
2590.0%0.25%
+27.7%
Q1 2020$49,000
-14.0%
2590.0%0.20%
+12.1%
Q4 2019$57,000
+11.8%
2590.0%0.17%
+3.6%
Q3 2019$51,000
-66.7%
259
-64.7%
0.17%
-61.1%
Q2 2019$153,000
+200.0%
734
+183.4%
0.43%
+149.7%
Q1 2019$51,000
+6.2%
2590.0%0.17%
+9.5%
Q4 2018$48,0002590.16%
Other shareholders
BIO-TECHNE CORP shareholders Q2 2024
NameSharesValueWeighting ↓
Summit Creek Advisors LLC 143,734$14,611,0003.07%
Brown Capital Management 2,147,690$218,313,0002.91%
STONE RUN CAPITAL, LLC 42,925$4,364,0002.62%
Select Equity Group, L.P. 2,432,176$247,230,690,0001.84%
MAIRS & POWER INC 1,389,850$141,278,0001.73%
Conestoga Capital Advisors, LLC 256,213$26,044,0001.57%
QUANTUM CAPITAL MANAGEMENT 59,798$6,078,0001.51%
First Light Asset Management, LLC 38,202$3,883,0001.48%
SEGALL BRYANT & HAMILL, LLC 570,853$58,027,0001.40%
RIVERBRIDGE PARTNERS LLC 604,797$61,478,0001.24%
View complete list of BIO-TECHNE CORP shareholders